Cells exposed to low-oxygen conditions (hypoxia) alter their metabolism to survive. This response, although vital during development and high-altitude survival, is now known to be a major factor in the selection of cells with a transformed metabolic phenotype during tumorigenesis. It is thought that hypoxia-selected cells have increased invasive capacity and resistance to both chemo-and radiotherapies, and therefore represent an attractive target for antitumor therapy. Hypoxia inducible factors (HIFs) are responsible for the majority of gene expression changes under hypoxia, and are themselves controlled by the oxygen-sensing HIF prolyl hydroxylases (PHDs). It was previously shown that mutations in succinate dehydrogenase lead to the inactivation PHDs under normoxic conditions, which can be overcome by treatment with a-ketoglutarate derivatives. Given that solid tumors contain large regions of hypoxia, the reactivation of PHDs in these conditions could induce metabolic catastrophe and therefore prove an effective antitumor therapy. In this report we demonstrate that derivatized a-ketoglutarate can be used as a strategy for maintaining PHD activity under hypoxia. By increasing intracellular a-ketoglutarate and activating PHDs we trigger PHD-dependent reversal of HIF1 activation, and PHD-dependent hypoxic cell death. We also show that derivatized a-ketoglutarate can permeate multiple layers of cells, reducing HIF1a levels and its target genes in vivo.
Introduction
Hypoxia, the marked reduction in available oxygen, can cause substantial cellular stress in the majority of cell types (Yoon et al., 2006; Simon and Keith, 2008) . To avoid this, cells starved of oxygen rapidly deploy a complex set of responses to enhance survival and reinstate a normal oxygen supply. These range from systemic responses, such as increasing the blood's oxygen delivery capacity, to cellular responses, such as the augmentation of glycolysis and reduction in ATP consumption (Goldberg et al., 1991; Semenza, 2000; Bracken et al., 2003; Ikeda, 2005) . The response to hypoxia has an imperative function in the pathogenesis of many diseases, as exemplified by ischemic disease following stroke or myocardial infarction, and in tumorigenesis (Semenza, 2001; Chandel and Simon, 2008) . During tumor formation, large hypoxic regions are created, providing a strongly stressful microenvironment that selects for cells with increased capacity for both metastasis and resistance to cell death (Rofstad, 2000; Brown and Wilson, 2004; Erler et al., 2004; To et al., 2005) . These are difficult areas to target due to their very nature-they have limited blood flow and in addition are more resistant to antitumor therapies than better-oxygenated areas. For this reason, therapies that directly target hypoxia, and more specifically hypoxia inducible factor (HIF), are still in their infancy.
The majority of the changes in gene expression observed in response to hypoxia are directed by HIFs, heterodimeric transcription factors that are inextricably linked to tumorigenesis (Maxwell et al., 2001) . These transcription factors induce the expression of genes that regulate processes including glycolysis (for example, Glut-1, LDHA), angiogenesis (for example, VEGF, ET-1), the modulation of tumor microenvironment (for example, LOX, CAIX) and cell death (for example, Bnip3) (Semenza, 2003) . HIF transcription factors consist of an a-and a b-subunit, both of which are members of the basic helix-loop-helix PAS (period circadian protein, arylhydrocarbon-receptor nuclear translocator, singleminded protein) family. Although a-and b-subunits are constitutively expressed, under normoxia the a-subunit is highly labile (Wang et al., 1995; Jiang et al., 1996) . The rapid degradation of HIFa is regulated by oxygendependent prolyl hydroxylase enzymes (PHDs), which hydroxylate two defined prolyl residues in its oxygendependent degradation (ODD) domain. This in turn recruits an E3 ubiquitin ligase complex containing pVHL, resulting in HIFa ubiquitylation and degradation by the proteasome. Owing to this efficient system, HIF1a has an extremely short half-life under normoxia (Maxwell et al., 1999; Berra et al., 2001) .
Prolyl hydroxylases, a group of enzymes that include both collagen hydroxylases and the PHDs, are members of the family of a-ketoglutarate-dependent dioxygenases (Schofield and Ratcliffe, 2004) . The genes encoding the PHDs were originally identified by virtue of their homology with a gene discovered in Caenorhabditis elegans which, when mutated, resulted in an egg-laying defective phenotype . Three paralogues of this gene, EGLN1, 2 and 3 have been described, the products of which will be referred to here as PHDs 2, 1 and 3, respectively (Bruick and McKnight, 2001; Epstein et al., 2001; Taylor, 2001) . These enzymes use oxygen, aketoglutarate and a prolyl residue as substrates, the products being a hydroxy-prolyl residue, succinate and CO 2 . Reports based on in vitro data indicate that the affinity of PHDs to oxygen is low (Km ¼ 230-250 mM), which make them good intracellular oxygen sensors (Hirsila et al., 2003) . There are data to suggest that levels of ascorbate and Fe(II) are also important for PHD activity. It has been shown that increasing ascorbate levels under hypoxia can increase PHD activity and therefore lead to HIF1a hydroxylation and degradation (Knowles et al., 2003; Lu et al., 2005; Gao et al., 2007) . This effect appears not to be ascorbate specific, as another antioxidant, N-acetylcysteine (NAC) can also decrease hypoxic HIF1a levels in a PHD2-dependent manner (Gao et al., 2007) . It is thought that ascorbate, and probably NAC, acts by reducing uncoupled enzymatic cycles undergone by PHDs and therefore allow for greater activity.
We and others have previously demonstrated that in cells with a deficiency in the enzyme succinate dehydrogenase (SDH) increased levels of succinate competitively inhibit PHDs even in the presence of oxygen, resulting in a pseudohypoxic phenotype characterized by HIF induction Selak et al., 2005) . We reported that cell-permeating a-ketoglutarate derivatives reversed succinate-mediated HIF stabilization by reactivating the PHDs in normoxic conditions (MacKenzie et al., 2007) . These studies suggested that it may be possible to reverse the inhibition of the PHDs by low oxygen, resulting in low HIF expression in hypoxic conditions. We show here that PHDs can be reactivated under hypoxia by derivatized a-ketoglutarate and that this results in the destabilization of HIF, reversal of the hypoxic-mediated increase in glycolysis and cell death. Using a xenograft tumor model, we also show that after oral dosing of derivatized a-ketoglutarate, intratumoral levels of a-ketoglutarate increase, resulting in reduced HIF1a levels, decreased transactivational activity and a decrease in glucose metabolism.
Results
Derivatized a-ketoglutarate destabilizes HIF1a and increases VHL binding under hypoxia We have previously reported that cell-permeating a-ketoglutarate derivatives efficiently reversed the pseudohypoxic phenotype present in SDH-deficient cells by reactivating PHDs (MacKenzie et al., 2007) . Therefore we investigated the possibility that increasing intracellular levels of a-ketoglutarate would similarly reactivate HIF PHDs in hypoxic cells. Using the previously described cell-permeable esterified form of a-ketoglutarate (1-trifluoromethyl benzyl-a-ketoglutarate, TaKG; MacKenzie et al., 2007), we preincubated the colon carcinoma, HCT116, cell line in normoxic (21%) or hypoxic (1%) conditions before being treated with TaKG ( Figure 1a ). Intracellular levels of nonesterified a-ketoglutarate were increased under both conditions, albeit transiently. Interestingly, this increase was more pronounced under hypoxia, perhaps because of the decrease in a-ketoglutarate dehydrogenase activity (the a-ketoglutarate utilizing step in the tricarboxylic acid (TCA) cycle) under hypoxia. It is worth noting that the concentrations of a-ketoglutarate measured reflect average cellular levels, and do not take into account variations that may occur between different compartments. Lysates from hypoxic cells treated with TaKG over a similar time course were immunoblotted and probed for HIF1a (Figure 1b) . Expression of this protein decreased significantly, mirroring the increase in intracellular a-ketoglutarate. This effect could also be observed in retinal pigment epithelial (RPE) and squamous cell carcinoma (A431) cell lines, indicating that this effect was not cell-type specific (Figure 1b) .
To investigate whether the effect of raising intracellular a-ketoglutarate on HIF1a was through the reactivation of PHDs, we generated a reporter cell line. HCT116 cells were transfected and selected to stably express a previously described fusion protein containing the ODD domain of HIF1a fused to green fluorescent protein (GFP) (GFP-ODD; MacKenzie et al., 2007) , herein called HCT116c18. As expected, PHD activity (which inversely correlated with GFP levels) was high in normoxia and decreased under hypoxia (Figure 1c , panels 1 and 2). The high GFP-ODD levels observed under hypoxia were not affected by exposure of cells to nonesterified a-ketoglutarate (panel 3). This is due to the fact that nonesterified a-ketoglutarate cannot cross the plasma membrane in this cell type, as shown in Figure 1d . Addition of the esterified, TaKG to the HCT116c18 cells resulted in the degradation of GFP-ODD, leading to GFP levels similar to those under normoxia (panel 4), indicating that PHDs can indeed be reactivated under hypoxia by a-ketoglutarate.
pVHL binds specifically to hydroxy-prolyl residues in the HIFa ODD, and therefore allows for the hydroxylation status of the GFP-ODD construct to be assessed. Hemagglutinin (HA)-tagged pVHL was transiently expressed in HCT116c18 cells, which were then treated with the proteasome inhibitor MG-132. HApVHL was co-immunoprecipitated with GFP-ODD under both normoxic and hypoxic conditions, with or without TaKG (Figure 1e ). Both HA-pVHL and GFP-ODD were detected at similar levels in all pre-IP conditions (lanes 1-4) (e) HCT116c18 cells, transiently transfected with HA-VHL, incubated at either 21% oxygen (lanes 1, 2, 5 and 6) or 1% oxygen (lanes 3, 4, 7 and 8) before treatment with MG-132. TaKG (2 mM ) was added where shown before lysis and co-immunoprecipitation using antigreen fluorescent protein (GFP) antibody. pVHL levels were assessed by western blot using anti-HA antibody.
Hypoxic reactivation of PHDs is through a-ketoglutarate-mediated increase in O 2 binding Prolyl hydroxylases can not only be inactivated by limiting oxygen conditions, but also by increasing succinate or fumarate (Isaacs et al., 2005; Lee et al., 2005; Selak et al., 2005; Hewitson et al., 2007; Koivunen et al., 2007) . To determine if increased succinate or fumarate was a factor in the hypoxic inactivation of PHDs, we measured the levels of some TCA intermediates ( Figure 2a) . Levels of almost all of the intermediates were decreased relative to their normoxic values, including succinate and a-ketoglutarate (Figures 2a and b) , indicating that succinate is unlikely to be a contributory factor in the hypoxic inactivation of the PHDs, and that it is most likely only the limitation of oxygen or a-ketoglutarate that results in PHD inhibition.
We therefore carried out a direct determination of whether increased a-ketoglutarate concentrations could reactivate hypoxic PHDs. To do this, a previously described in vitro hydroxylation assay was performed using an in vitro translated fusion protein containing the ODD domain of HIF1a and HA tag (Ivan et al., 2001; Huang et al., 2002) . in vitro translated peptide was used as a non-hydroxylated substrate ( Figure 2c , lane 1), and peptide incubated under normoxia with HCT116 cell extract (PHD source) and 10 mM a-ketoglutarate was used as a positive control (hydroxylated form, lane 6). When the reaction was performed under hypoxic conditions a significant inhibition of hydroxylation was observed (lane 2). By increasing the concentrations of a-ketoglutarate, the ratio of hydroxylated to non-hydroxylated peptide found under 1% oxygen increased proportionally (lanes 2-5), indicating a reactivation of the hydroxylase under hypoxia.
HIF1a destabilization by a-ketoglutarate is PHD2 and VHL dependent
To elucidate the precise mechanism by which a-ketoglutarate decreased HIF1a levels, we added the proteasomal inhibitor MG-132 to hypoxic cells before addition of TaKG. The decrease in HIF1a observed after treatment with TaKG was concurrent with the appearance of an HIF1a antibody-reactive, high molecular weight band suggestive of a ubiquitylated product ( Figure 3a ). This suggested that the E3 ubiquitin ligase, pVHL, may be involved in this response, so to test this the RCC4 cell line, which has no functional pVHL, was used alongside an isogenic clone of RCC4 cells in which pVHL was reexpressed. As expected, only the cell line lacking pVHL expressed HIF1a under normoxia ( Figure 3b , lane 2), although both expressed high levels of HIF1a under hypoxia (lanes 3 and 4). However, only the cells containing pVHL were able to degrade HIF1a after treatment with TaKG (lane 5): those lacking pVHL were unaffected. This indicates that pVHL is necessary for the a-ketoglutarate-mediated destabilization of HIF1a under hypoxia, and furthermore confirms hydroxylation of endogenous HIF1a under hypoxia as the mechanism of TaKG-mediated HIF1a elimination.
In a further experiment, HCT116 cells were transiently transfected with a previously described mutated, Myctagged form of murine HIF1a, in which prolines 402 and 577, and asparagine 813 were mutated to alanine (Hu et al., 2007) . This protein, which is resistant to PHD- mediated hydroxylation, was not degraded after treatment with TaKG (Figure 3c ), providing further evidence of the mechanism of action of this compound.
It has been shown that PHD2 is the major isoform responsible for the low normoxic levels of HIF1a (Berra et al., 2003) . To test whether this is also the isoform responsible for the a-ketoglutarate-mediated destabilization of HIF1a under hypoxia, the expression of both PHD2 and 3 was knocked down using siRNA (Figure 3d) , and PHD1 by shRNA ( Figure 3e ). As previously described, normoxic levels of HIF1a were increased only when PHD2 was knocked down (Figure 3d , lanes 2 and 4; Berra et al., 2003) . Under hypoxia, HIF1a was further stabilized by PHD2 knockdown, indicating that the enzyme may not be completely inactive at 1% oxygen (compare lanes 5 and 6). PHD3 knockdown, however, had no effect. After treatment with TaKG, levels of hypoxic HIF1a in both control and PHD3 knockdown samples were decreased (lanes 9 and 11) but remained similar to hypoxic levels in the PHD2 knockdown (lanes 10 and 12). PHD1 knockdown also had little effect on HIF1a destabilization after a-ketoglutarate treatment (Figure 3e ). This indicates that PHD2 is the major target for the a-ketoglutaratemediated reduction in HIF1a expression under hypoxia, with PHDs 1 and 3 having little or no role in this process.
Increasing a-ketoglutarate derivative stability further destabilizes HIFa As previously mentioned, TaKG only provides a transient increase in intracellular a-ketoglutarate levels ( Figure 1a) . To stabilize the increase in intracellular levels of a-ketoglutarate, we ethylated the free carboxylic group of TaKG to form a diester, ETaKG (1-trifluoromethylbenzyl, 5-ethyl a-ketoglutarate). This new compound was found to be more stable in aqueous solution (Figure 4a) , with little degradation observed over 2 h. As with the TaKG treatment, ETaKG produced an increase in intracellular a-ketoglutarate, which was potentiated by hypoxia ( Figure 4b ). However, the increased stability of the compound produced a greater, more prolonged increase in intracellular a-ketoglutarate than TaKG, with levels still 15-fold above control after 4 h. A biphasic rise in the intracellular concentration of a-ketoglutarate was noted. This may be related to the two de-esterification steps required for converting ETaKG to free a-ketoglutarate in the cells but this has not yet been fully characterized.
To test whether this compound could also destabilize hypoxic HIF1a, we used ETaKG to treat hypoxic HCT116, RPE and A431 cells. Lysates were immunoblotted with HIF1a ( Figure 4c ) and all showed a decrease in HIF1a levels. Interestingly, ETaKG, unlike TaKG, was also able to destabilize HIF2a (Figure 4d ), suggesting that HIF1a and 2a are hydroxylated by different PHDs with different thresholds of reactivation by a-ketoglutarate.
PHD reactivation under hypoxia results in metabolic catastrophe
The HIF1 transcription factor orchestrates the increased glycolysis and resultant lactate production observed under hypoxia: processes vital for hypoxic ATP production. To investigate the functional consequences of PHD reactivation under hypoxia, both lactate and glucose uptakes were measured. As expected, the cells under hypoxia increased lactate production (Figure 5a ), which was significantly reversed by the addition of TaKG. To examine whether the change in lactate production was due to a decrease in glycolysis, we measured glucose uptake using the fluorescent glucose derivative, 6-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-6-deoxyglucose (6-NBDG), which is phosphorylated by hexokinase and retained in the cytosol after uptake. As expected, glucose uptake was greatly increased by hypoxia (Figure 5b ), an effect that was also reduced by treatment with TaKG. Finally, intracellular ATP levels were measured under these conditions. Although there was little change in ATP levels under hypoxia, treatment of hypoxic cells with TaKG greatly decreased cellular ATP (Figure 5c ).
Increasing a-ketoglutarate in hypoxia results in PHD2-and 3-dependent cell death Sustained suppression of glycolytic ATP production under hypoxia should induce cell death. Figure 6a shows that when normoxic cells were treated with TaKG, plasma membrane integrity was preserved, as assessed by propidium iodide (PI) exclusion (top right panel). However, hypoxic cells treated with TaKG over the same time period showed high levels of PI staining consistent with cell death (bottom right panel). This was confirmed by analysing cells treated with ETaKG over 4 h for PI fluorescence by flow cytometry (Figure 6b ). Normoxic cells treated with ETaKG showed little increase in cell death. However, addition of ETaKG to hypoxic cells resulted in around 40% cell death: an effect that was not inhibited by the pan-caspase inhibitor, zVAD (Figure 6b) , indicating a non-apoptotic form of cell death. Cells were then transiently transfected with siRNA against PHD2 or PHD3 (or non-silencing control). Knockdown of PHD2 or PHD3 partially reversed the cell death observed (Figure 6c ), indicating that this effect was, at least in part, PHD2 and 3 dependent.
Esterified a-ketoglutarate can permeate 3D cell structures and reactivate PHDs To test whether a-ketoglutarate derivatives could reactivate PHDs in a more physiologically relevant system, we generated spheroids of HCT116 and the GFP-ODD expressing HCT116c18 cells. The hypoxic region of untreated, HCT116c18 spheroids, expressed high levels of GFP, indicative of low PHD activity (Figure 7a ). However, those treated with TaKG reversed the hypoxic induction of GFP, indicating that the PHDs were reactivated throughout the cell mass. To confirm this, sections from parental HCT116-derived spheroids were assessed for HIF1a expression and the HIF1a target gene, glucose transporter-1 (Glut-1) (Figures 7b  and c) . Levels of both proteins were decreased 4 h after treatment, indicating that this derivative can penetrate multiple layers of cells and efficiently destabilize HIF1a.
Treatment of xenograft tumors with ETaKG reverses hypoxic physiology
Hypoxia inducible factor-mediated changes in cell physiology assist tumor formation and growth, therefore if these changes could be reversed or modulated, tumorigenesis may be inhibited. To investigate whether the a-ketoglutarate derivatives were able to reactivate PHDs in vivo, and therefore destabilize HIFa expression in tumors, a study was performed in which mice bearing xenograft tumors of A375 cells, measuring , were given a single oral dose of ETaKG. At 90 min after dosing, tumors were harvested and analysed for levels of a-ketoglutarate. Figure 7d shows that intratumoral a-ketoglutarate concentration was almost doubled after treatment, indicating that this derivative is capable of increasing intratumoral aketoglutarate after oral dosing. To assess the effects of this increase, tumors were removed 6 h after dosing and fixed. Tumor sections from each mouse were immunostained for HIF1a, or the HIF target genes; Glut-1 or carbonic anhydrase IX (CAIX). Expression levels of all three proteins were reduced after treatment with ETaKG ( Figure 7e ). These data strongly suggest that the diester form of a-ketoglutarate can indeed reactivate PHDs and destabilize HIF1a, in vivo, resulting in the subsequent reduction in target genes of this transcription factor.
Finally, we noted in vitro, that treatment with aketoglutarate derivatives could reduce the hypoxiamediated increase in glucose uptake. To test whether ETaKG would reverse the expected increase in glucose uptake and metabolism in vivo, [
18 F]-2-deoxyglucose (FDG, a radiolabeled, non-metabolizable glucose derivative) was administrated to xenograft-bearing mice 3 h after treatment with vehicle or with ETaKG (as above) and was followed by positron emission tomography (PET) for another hour. ETaKG treatment reduced FDG accumulation in tumors as compared to vehicletreated mice (Figures 7f and g ), although this decrease in glucose uptake returned to normal levels within 6-9 h after treatment.
Discussion
Adaptation to hypoxic conditions is vital for cell survival and in tumors represents a major selective pressure in increasing their aggressiveness (BrahimiHorn et al., 2007) . Key to this process are thought to be the HIFa transcription factors, as in a number of tumor types, HIF1a expression has been correlated with negative prognosis or survival (Aebersold et al., 2001; Birner et al., 2001; Khatua et al., 2003) . Several studies have correlated HIF1a nuclear expression with tumor progression (Talks et al., 2000) , and repression of HIF1a transcription has also been shown to decrease tumor growth (Maxwell et al., 1997) .
In this study, we propose a novel way of targeting the alterations in cellular physiology produced by hypoxia. We show that PHDs can be reactivated in hypoxia by increasing intracellular a-ketoglutarate, and that this results in destabilization of HIFa subunits and the perturbation of the hypoxic metabolism necessary for survival. Interestingly, we found that as succinate levels decreased under hypoxia, it is unlikely that it is involved in the hypoxic inhibition of PHDs, leading to the conclusion that either lack of oxygen or a-ketoglutarate mediates this effect. Indeed, in the in vitro hydroxylation assay, increasing a-ketoglutarate alone resulted in increased hydroxylation activity in the extract. Interestingly, there are data indicating that increasing levels of ascorbate can reactivate PHDs in hypoxia (Lu et al., 2005; Gao et al., 2007) . The data from our in vitro hydroxylation assay suggest that under these conditions the concentration of ascorbate has a limited role in hypoxia-mediated PHD inhibition. The reversal of hypoxic PHD inhibition solely by increasing intracellular a-ketoglutarate suggests that levels of this substrate, under limited oxygen, can be sufficient to determine PHD activity and therefore cellular metabolism. This does not rule out the possibility that increasing intracellular a-ketoglutarate in combination with greater amounts of exogenous ascorbate could act synergistically in decreasing HIFa for more extended periods of time.
Under normoxia, it is understood that the major PHD responsible for the hydroxylation of HIF1a is PHD2. This appears to hold true when PHDs are reactivated under hypoxia, as knockdown of either PHD1 or 3 had little effect on the destabilization of HIF1a under hypoxia. This does not indicate that PHDs 1 or 3 are not also reactivated under these conditions, only that we were unable to determine specifically their activity due to a lack of characterization of their targets. It is of interest that the effect of ascorbate on HIF1a was also found to be PHD2 dependent, suggesting similar mechanism of action (Gao et al., 2007) .
It has previously been shown that under hypoxia, a number of gene expression changes occur that alter the major ATP-generating mechanism in the cells (Papandreou et al., 2006) . These changes include an increase in glycolytic enzyme expression and isoform selection, the diversion of pyruvate away from the mitochondrion (Kim et al., 2006; Papandreou et al., 2006) and alterations in the affinity of the electron transport chain (cytochrome c oxidase) to oxygen (Fukuda et al., 2007) , all of which are HIF1a dependent. However, the publication of the PHD1 knockout mouse has also raised the possibility that reactivating PHD1 under hypoxia could have effects on cellular metabolism independently of HIF1a (Aragones et al., 2008) . This may well be involved in the effect observed after aketoglutarate treatment, and requires further characterization. In this study, by increasing intracellular aketoglutarate, we decreased both glucose uptake both in vitro and in vivo, and lactate production, which suggested a decrease in glycolytic flux. In these conditions, where cells are less able to use oxygen to synthesize ATP, the reduction in glycolytic flux resulted in a drop in cellular ATP, and ultimately cell death. This would also be predicted to occur in vivo, and studies are currently underway to determine the effect of the esterified a-ketoglutarate on tumor growth. Interestingly, the cell death observed in vitro was not only found to be PHD2 dependent, but also partially due to PHD3. This therefore suggests an a-ketoglutarate-induced, caspase-independent mode of cell death, which is at least partly HIF1a independent. Supporting evidence for the presence of PHD-dependent, HIF-independent cell death mechanisms highlights PHD3 as having a proapoptotic effect under normoxia in a number of cell types Bishop et al., 2008; Schlisio et al., 2008) . It is important to observe that knockdown of either PHD2 or 3 failed to ablate completely the hypoxia-specific cell death response. Although this could well be due to the fact that the knockdown achieved was incomplete or that there may be more than one PHD-dependent signaling mechanism triggering this cell death, this could indicate PHD-independent cell death mechanisms under these conditions. These could involve aberrant activation of other a-ketoglutarate-dependent dioxygenases or inappropriate TCA cycle activity causing mitochondrial dysfunction.
The global changes in cellular metabolism and survival mechanisms induced by hypoxia are vital for continuing cell viability under chronic hypoxia and are important factors in the creation of malignancies. By reversing these changes, we can effectively bring about a normoxic phenotype in a hypoxic environment-a condition that is incompatible with cell survival and tumor development.
Materials and methods
Plasmids, siRNA and transfections pRK5/HA-ODD and pEGFP/ODD, which were used for in vitro translation of HA-ODD or for expressing the GFP-ODD fusion protein, respectively, were described previously (Selak et al., 2005) . pRC-CMV/HA-pVHL was used to coexpress HA-pVHL in the GFP-ODD-expressing clones and was a gift from WG Kaelin Jr, and previously published murine HIF1a triple mutant (P402A/P577A/N813A) was a kind gift from MC Simon (Hu et al., 2007) . PHD2 and 3 siRNA sequences were as previously described (Appelhoff et al., 2004) and synthesized by Eurofins (Ebersberg, Germany). PHD1 and GFP shRNA plasmids were obtained from Open Biosystems (Thermo Scientific, Rockford, IL, USA) (RHS3979-9589732 and RHS4459, respectively). All transfections were performed with Lipofectamine 2000 (Invitrogen, Paisley, UK) using standard protocols.
Synthesis of a-ketoglutarate derivatives 2-Oxopentanedioic acid 4-(1-trifluoromethylbenzyl) ester (TaKG) was synthesized as previously described (MacKenzie et al., 2007) . 2-Oxopentanedioic acid 5-ethyl,4-(1-trifluoromethylbenzyl) ester (ETaKG) was synthesized using the same techniques by Domainex (Cambridge, UK).
Cell culture
Human colon carcinoma (HCT116), renal clear cell carcinoma (RCC4 ± VHL), squamous cell carcinoma (A431), melanoma (A375) and RPE cells were cultured using standard procedures in a 37 1C humidified incubator with 5% CO 2 . All lines were cultured in high-glucose Dulbecco's modified Eagle's medium (Invitrogen) with 10% heat-inactivated fetal bovine serum and 2 mM glutamine. HCT116c18 cells were generated by transfecting pEGFP/ODD into HCT116 cells followed by selection in G418. After picking colonies, clones were selected for low normoxic GFP expression and high expression when incubated with CoCl 2 overnight. Hypoxia was achieved using a humidified, Invivo2 500 hypoxic chamber (Biotrace, Bridgend, UK) and Ruskin hypoxic gas mixer at 37 1C with 1% O 2 , 5% CO 2 and 94% N 2 unless otherwise specified. To prepare spheroids, we plated 20 ml of HCT116 cells (both untransfected and c18) at 10 5 per ml onto 10 cm culture dishes containing 0.5% low-melting-point agarose diluted in growth medium. After approximately 3 days of growth spheroids were filtered to retain those with a diameter of greater than 70 mm. These were transferred to a spinner culture flask and grown until the diameter was 300-500 mm. Spheroids were treated in 5 ml volumes in 15 ml conical tubes on a roller. Samples were treated twice for 2 h with 2 mM of TaKG, ETaKG, or a combination of trifluoromethylbenzoate and a-ketoglutarate as control. Spheroids were either immediately imaged (using Olympus CX41 microscope with QImaging camera and QCapture-Pro software) or allowed to settle, washed twice with phosphate-buffered saline (PBS) and then fixed in 10% neutral buffered formalin overnight at 4 1C. Spheroids were then washed with PBS before being resuspended in molten 2% agarose.
Immunoprecipitation
HCT116c18 cells were transfected with HA-VHL plasmid 24 h before incubation in 21 or 1% oxygen. After 4 h, 10 mM MG-132 was added to all cells for 6 h. TaKG (2 mM) was then added to the plates to be treated, and after an hour, cells were washed in cold PBS and lysed in Tris-buffered saline and 0.05% NP-40. After protein quantitation by BCA assay, 30 mg was removed for 'total' sample, and 3 mg was used for immunoprecipitation. After preincubation with protein Asepharose beads, lysate was incubated with 3 mg anti-GFP antibody (MBL, Woburn, MA, USA) for 1 h before protein Asepharose beads were added and incubated for a further 1.5 h. After washing the beads, proteins were eluted in Laemmli and analysed by SDS-polyacrylamide gel electrophoresis (PAGE).
Immunoblotting Cells were extracted in Laemmli unless otherwise stated. After SDS-PAGE, proteins were blotted onto nitrocellulose and analysed with the following antibodies: HIF1a (BD Biosciences, Erembodegem, Belgium), HIF2a (EP190b; Cancer Research UK monoclonal service, London, UK), pVHL (BD Pharmingen, Erembodegem, Belgium), GFP (BD Biosciences, Oxford, UK), HA (horseradish peroxidase conjugated; Roche, Burgess Hill, UK), Myc tag (4A6; Millipore, Watford, UK), PHD1 (Aviva Systems Biology, San Diego, CA, USA), PHD2 and 3 (kind gifts from Kevin Gatter) or actin (AC-40; Sigma, Gillingham, UK). in vitro hydroxylation assay pRK5 HA-ODD was in vitro translated using wheat germ extract (Promega). Total cell extract was prepared from HCT116 cells that had been incubated under hypoxic conditions (1% oxygen overnight) by lysing in 20 mM Tris (pH 7.4), 5 mM KCl, 1.5 mM MgCl 2 , 1 mM DTT, supplemented with complete protease inhibitor cocktail (Roche). All reagents were deoxygenated by bubbling with nitrogen and equilibrating at 1% oxygen. in vitro hydroxylation was carried out by incubating 5 ml in vitro translated HA-ODD with 50 ml cell extract. Reactions were carried out for 30 min at 37 1C in the presence of 5 mM ascorbate, 100 mM FeCl 2 , 100 mM ALLN and a-ketoglutarate as indicated. Reactions were terminated by adding Laemmli sample buffer and boiling. Samples were analysed by western blot using an anti-HA antibody.
Intracellular a-ketoglutarate assay Cells were grown under indicated conditions. All operations were performed at 4 1C. Cell monolayers were washed with PBS and lysed with RIPA buffer. Cell lysates were collected from the plate, and centrifuged for 5 min at 15 000 g at 4 1C. Aliquots of the extracts were analysed immediately for aketoglutarate. For tumor samples, after being weighed, tumors were pulverized on liquid N 2 and then extracted using perchloric acid as previously described (Williamson and Corkey, 1979) . The assay buffer consisted of the following: 100 mM KH 2 PO 4 (pH 7.2 at 37 1C), 10 mM NH 4 Cl, 5 mM MgCl 2 and 0.15 mM NADH. Extract was added to the warmed buffer (37 1C), and the reaction started by addition of 5 U glutamate dehydrogenase. Absorbance decrease was monitored at 340 nm. The intracellular concentration of a-ketoglutarate was determined from the absorbance decrease in NADH (e ¼ 6.22 mM À1 cm À1 ), and average cell volume was determined from a trypsinized well of cells using a cell counter (CASY 1; Scha¨rfe Systems, Reutlingen, Germany).
TCA cycle intermediate measurements HCT116 cells were incubated under either 21 or 1% oxygen for 36 h before harvesting with PBS wash and scraping into ice-cold 80% methanol/20% water. After 15 min on ice, the insoluble material was pelleted in a cooled centrifuge before freezing the supernatant at À20 1C. Intermediates were identified using a liquid chromatography system (Finnigan Surveyor Autosampler Plus; Thermo Fisher Scientific, San Jose, CA, USA and MS Pump Plus; San Jose, CA, USA) with a Sequant Zic-Hilic (150 Â 4.6 mm, i.d. 5 mm) column and guard column (20 Â 2.1 mm, i.d. 5mm; Merck KGAA, Darmstadt, Germany). Samples were run on a gradient with the following mobile phases: (1) 0.1% formic acid (v/v) in water; (2) 0.1% formic acid (v/v) in acetonitrile with a flow rate of 300 ml/min. The LC system was coupled online to an LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) equipped with an electrospray ionization source, and data acquisition was controlled with Xcalibur 2.0 (Thermo Fisher). All metabolites were measured by a full scan from m/z 50 to m/z 1200 with a resolution of 30 000. Alignment, framing and statistical analysis were processed by Sieves 1.2 Beta (Thermo Fisher).
Lactate, ATP and glucose uptake assays Cells were grown as indicated and culture medium was used directly in the lactate assay as per manufacturer's instructions (Trinity Biotech, Theale, UK). Lactate levels were assayed spectrophotometrically (540 nm) and compared against a known standard. Glucose uptake was measured by adding 30 mM of the fluorescence glucose analogue, 6-NBDG (Invitrogen, Paisley, UK), to the culture medium at the end of treatment, before washing, trypsinizing and analysing the cells using flow cytometry (FACSCalibur; Beckton Dickinson, Oxford, UK). ATP was measured from the cell lysates of the same samples using a luciferase-based assay as per manufacturer's instructions (Sigma).
